Update on Guildford paddling pool plagued by problems
Respiratory problems
Council leader Julia McShane told BBC Radio Surrey that the current high levels of chlorine in the water could be a public health risk.She said it would particularly affect vulnerable people and might lead to skin or eye irritation as well as stomach and breathing problems."We don't want to be causing people those issues to their health," she said.
"I can reassure people that the teams are working incredibly hard with experts to try to find out what the problem is and to resolve this as quickly as possible so we can get this pool open again."But with temperatures in Guildford set to hit 32C on Monday, many families have been left feeling frustrated."It doesn't seem like they can get it right on anything really, it's a real shame that it's like that again, we had a lovely summer here last year once it was sorted," one parent said.Another told us: "We're all sad because we used it last year and it was lovely, a lot of people enjoyed being there, but unfortunately it's not open."
What happens now?
Ms McShane said it would not be fair to give a reopening date to the public as a timeframe for repairs is not yet clear, but she did say work would continue from next week."The team are going to empty the pool again, flush it through, fill it back up again, probably try a different chemical treatment and then test it again," she said."When we're absolutely certain that the pool is safe to use, then we'll reopen."And how much is this all costing?Ms McShane was unable to give a figure and the council did not provide us with one either when we followed it up.So, for now, families will just have to keep their fingers crossed and hope the sun is still around when the pool eventually reopens.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
19 minutes ago
- The Independent
Why London hospital was forced to evacuate
Guy's Hospital in Southwark, London, was evacuated on Thursday morning due to a chlorine gas leak caused by the accidental mixing of chemicals in a boiler room. Approximately 150 people were evacuated from the basement and ground floor of the hospital shortly before 9 am. Nine individuals were attended to by the London Ambulance Service at the scene, with four subsequently requiring hospital treatment. One staff member was injured in the incident, and several people who came to their aid were also treated for chlorine gas inhalation. Firefighters and specialist hazardous materials officers attended the scene, ventilating the building, which has since reopened for appointments.
The Independent
an hour ago
- The Independent
Baroness Amos to lead NHS maternity and neonatal investigation
The Royal College of Midwives (RCM) has welcomed the selection of Baroness Valerie Amos to lead the investigation into NHS maternity and neonatal care, adding it is 'vital' the review gets under way quickly. Baroness Amos was selected by Health Secretary Wes Streeting after bereaved families expressed a preference for someone with distance from the NHS who is able to bring a fresh pair of eyes to the role, the Department of Health and Social Care (DHSC) said. Mr Streeting has been meeting bereaved and harmed families who have been let down by maternity and neonatal services across the country, including in some of the worst affected trusts, DHSC added. In June, he announced that a national investigation into 'systemic' failures in NHS maternity care had been launched by the Government after families were 'gaslit' in their search for the truth. Baroness Amos is master of University College, Oxford, and was a UK Government minister and a senior official at the United Nations. Mr Streeting said: 'I have been appalled by the many harrowing stories I've heard from mothers and fathers let down by the NHS. ' Families asked for fresh eyes, independence and compassion – and that's why I've appointed Baroness Amos. Valerie has an outstanding record of leadership and driving change, nationally and internationally. She will work closely with families to uncover the truth, confront problems and drive the improvements needed so every woman and baby receives safe, high-quality care. 'Through our Plan for Change, we will rebuild the NHS to ensure no family suffers like this again.' Baroness Amos said: 'I will carry the weight of the loss suffered by families with me throughout this investigation. I hope that we will be able to provide the answers that families are seeking and support the NHS in identifying areas of care requiring urgent reform.' The investigation will look at up to 10 services in the country. It will also review the maternity and neonatal system, bringing together the findings of past reviews into one national set of actions, the DHSC said. It will begin work this summer and produce an initial set of national recommendations by December. The 10 maternity and neonatal units will be decided by Baroness Amos and her team, alongside the terms of reference of the investigation, which are being developed with families who have experiences of maternity and neonatal care, including in Leeds, Sussex and Nottingham, the DHSC added. The investigation is separate from the National Maternity and Neonatal Taskforce, which will be made up of a panel of experts and families, and chaired by Mr Streeting. Gill Walton, chief executive of the RCM, said: 'We are pleased to hear of the appointment of Baroness Amos as chair of the rapid review. She has a reputation for taking a thoughtful and strategic approach and we welcome her fresh insight into maternity and neonatal safety. 'It is absolutely vital, though, that this review gets under way quickly. When he announced it in June, we welcomed Wes Streeting's commitment to publishing the review by Christmas, a promise he repeated at the Progress in Partnership summit on maternity and neonatal safety last month. 'However, we are already halfway through August, with no terms of reference, no sense of the trusts who are likely to be part of the review or no clarity on how the review will be conducted. 'Every woman and family should leave maternity and neonatal services whole, happy and healthy, and every member of maternity staff should start and end their shift knowing they have provided safe, good-quality care. 'At the moment, that simply isn't the case. Previous reviews and countless Care Quality Commission reports have flagged the same the systemic failings that are at the heart of the issues facing maternity and neonatal care issues time and time again: unsafe staffing, poor workplace cultures, and not listening to women. 'In spite of that, there has been no forward movement. Wes Streeting promised to change that. Thousands of midwives and maternity support workers, and the whole of the maternity community, are desperate for him to keep that promise and deliver the change we all want to see.' The RCM has also urged the review to look at examples of good maternity care, as well as where services are not meeting standards of care.
Telegraph
an hour ago
- Telegraph
AI antibiotics for superbugs could lead to ‘golden age of discovery'
Artificial intelligence has created two antibiotics that could herald a 'golden age' in the fight against superbugs. AI virtually invented more than 50 million compounds and investigated whether they could kill MRSA and gonorrhoea, two of the most common superbugs. More than 52,000 people a year in the UK catch antibiotic-resistant infections, which cause around 2,000 deaths annually. Antimicrobial resistance, which creates superbugs, has been called the 'silent pandemic' and the problem of antibiotic resistance is set to get worse. These deadly infections occur when a bacteria is treated with a drug but works out ways of neutralising the medicine. The genetic protections make drugs less effective and can make common infections lethal. Researchers at the Massachusetts Institute of Technology (MIT) used AI to come up with completely new ways of targeting these pathogens in the hope of making a breakthrough against superbugs. 'We're excited because we show that generative AI can be used to design completely new antibiotics,' Prof James Collins, the leader of the project at MIT, told the BBC. 'AI can enable us to come up with molecules, cheaply and quickly and in this way, expand our arsenal, and really give us a leg up in the battle of our wits against the genes of superbugs.' AI was used to make as many hypothetical chemical compounds as possible that could target and kill the two bacterial infections. The algorithms then filtered the results to show only those that worked in a novel way, had strong antimicrobial properties and were not toxic. This left one million possible new antibiotics in the virtual database. Dr Aartia Krishnan, a postdoctoral researcher at MIT, said this step was key because the team's goal was to find drugs that worked in a completely different way to anything else ever used by doctors. Scientists then tried to physically make around 170 of the most promising compounds. Only 24 of the chemicals could be created in a lab, with two for gonorrhoea and 22 against MRSA. Tests in cells and mice found one of the novel gonorrhoea antibiotics and one of the MRSA compounds were able to kill bacteria. 'Both compounds exhibited mechanisms of action distinct from those of often-used antibiotics and were effective in reducing bacterial titers in different animal models of infection,' the study authors wrote in their paper, published in Cell. 'Additionally, both compounds exhibited a structure-activity landscape that can be productively used for further optimisation. 'Together, our results enable the generative design of two unique structural classes of antibacterial compounds and demonstrate the ability of our platform to explore uncharted regions of chemical space.' A company affiliated with the MIT research project is now investigating if the two antibiotics, dubbed NG1 and DNA1, can be adapted for preclinical trials. 'We are exploring analogues, as well as working on advancing the best candidates preclinically, through medicinal chemistry work,' said Prof Collins. 'We are also excited about applying the platforms that Aarti and the team have developed toward other bacterial pathogens of interest, notably Mycobacterium tuberculosis and Pseudomonas aeruginosa.'
